Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents — Toshiharu Sakurai (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents
Shared by
Masatoshi Kudo
Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents
Letter
2020
en
Authors
TS
Toshiharu Sakurai
NN
Naoshi Nishida
Masatoshi Kudo
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2020
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann‐Lii Cheng
,
Chiun Hsu
,
Stephen L. Chan
,
Su Pin Choo
,
Masatoshi Kudo
Article
2020
Immunomodulation by targeted anticancer agents
Giulia Petroni
,
Aitziber Buqué
,
Laurence Zitvogel
,
Guido Guido Kroemer
,
Lorenzo Galluzzi
Article
2015
Prime time for immune-checkpoint targeted therapy at ASCO 2015
Aurélien Marabelle
,
Bertrand Routy
,
Judith Michels
,
Guido Guido Kroemer
,
Laurence Zitvogel
Article
2021
Immune checkpoint inhibitors
Guido Guido Kroemer
,
Laurence Zitvogel
Article
2015
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi
,
Aitziber Buqué
,
Oliver Kepp
,
Laurence Zitvogel
,
Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.